NasdaqCM - Nasdaq Real Time Price USD

Sonoma Pharmaceuticals, Inc. (SNOA)

3.0500

+0.0200

+(0.66%)

At close: May 7 at 4:00:00 PM EDT

3.0500

0.00

(0.00%)

Pre-Market: 4:47:26 AM EDT

Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain

BOULDER, CO / ACCESS Newswire / April 22, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ...

ACCESS Newswire 15 days ago

SNOA
+0.66%
Fast-paced Momentum Stock Sonoma Pharmaceuticals (SNOA) Is Still Trading at a Bargain

Sonoma Pharmaceuticals (SNOA) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Zacks last month

SNOA
+0.66%
Delaware passes law designed to stop more Elon Musks from leaving state

Delaware lawmakers pushed through controversial changes governing corporate behavior in a scramble to keep more businesses from leaving the state following Elon Musk's dramatic exit.

Yahoo Finance last month

TSLA

SPAX.PVT

META
Why Fast-paced Mover Sonoma Pharmaceuticals (SNOA) Is a Great Choice for Value Investors

Sonoma Pharmaceuticals (SNOA) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks last month

SNOA
+0.66%
Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)

BOULDER, CO / ACCESS Newswire / March 10, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ...

ACCESS Newswire last month

SNOA
+0.66%
Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando

BOULDER, CO / ACCESS Newswire / February 25, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of ...

ACCESS Newswire 2 months ago

SNOA
+0.66%
Is Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Worth US$2.7 Based On Its Intrinsic Value?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Sonoma Pharmaceuticals fair value estimate is US$1.97 Sonoma...

Simply Wall St. 2 months ago

SNOA
+0.66%
Sonoma Pharmaceuticals Third Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Sonoma Pharmaceuticals ( NASDAQ:SNOA ) Third Quarter 2025 Results Key Financial Results Revenue: US$3.56m (up 14% from...

Simply Wall St. 2 months ago

SNOA
+0.66%
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results

Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, ...

ACCESS Newswire 2 months ago

SNOA
+0.66%
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices

Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and ...

ACCESS Newswire 4 months ago

SNOA
+0.66%
Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain Stock

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks 5 months ago

SNOA
+0.66%
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States

BOULDER, CO / ACCESSWIRE / November 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ...

ACCESS Newswire 5 months ago

SNOA
+0.66%
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel

BOULDER, CO / ACCESSWIRE / November 11, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ...

ACCESS Newswire 5 months ago

SNOA
+0.66%
Sonoma Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Sonoma Pharmaceuticals ( NASDAQ:SNOA ) Second Quarter 2025 Results Key Financial Results Revenue: US$3.58m (up 31% from...

Simply Wall St. 5 months ago

SNOA
+0.66%
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results

Revenue increased 31% for the quarter compared to same period prior year Positive cash flows from operations of $0.35 million for the quarter Net loss improved 59% for the quarter compared to same period prior year Net loss per share improved 90% ...

ACCESS Newswire 5 months ago

SNOA
+0.66%
Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf

BOULDER, CO / ACCESSWIRE / October 31, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ...

ACCESS Newswire 6 months ago

SNOA
+0.66%
Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada

BOULDER, CO / ACCESSWIRE / October 22, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ...

ACCESS Newswire 6 months ago

SNOA
+0.66%
Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor Conferences

BOULDER, CO / ACCESSWIRE / October 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ...

ACCESS Newswire 6 months ago

SNOA
+0.66%
Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

BOULDER, CO / ACCESSWIRE / September 19, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ...

ACCESS Newswire 7 months ago

SNOA
+0.66%
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution

BOULDER, CO / ACCESSWIRE / September 17, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ...

ACCESS Newswire 7 months ago

SNOA
+0.66%

Performance Overview

Return	SNOA	S&P 500 (^GSPC)
YTD	+13.38%	-4.26%
1-Year	+1.67%	+8.55%
3-Year	-95.88%	+36.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sonoma Pharmaceuticals, Inc. (SNOA)

Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain

Fast-paced Momentum Stock Sonoma Pharmaceuticals (SNOA) Is Still Trading at a Bargain

Delaware passes law designed to stop more Elon Musks from leaving state

Why Fast-paced Mover Sonoma Pharmaceuticals (SNOA) Is a Great Choice for Value Investors

Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)

Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando

Is Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Worth US$2.7 Based On Its Intrinsic Value?

Sonoma Pharmaceuticals Third Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results

Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices

Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain Stock

Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States

Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel

Sonoma Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results

Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf

Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada

Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor Conferences

Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution

Performance Overview